[go: up one dir, main page]

MX9704640A - Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. - Google Patents

Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.

Info

Publication number
MX9704640A
MX9704640A MX9704640A MX9704640A MX9704640A MX 9704640 A MX9704640 A MX 9704640A MX 9704640 A MX9704640 A MX 9704640A MX 9704640 A MX9704640 A MX 9704640A MX 9704640 A MX9704640 A MX 9704640A
Authority
MX
Mexico
Prior art keywords
compounds
steroid receptor
methods
receptor modulator
disclosed
Prior art date
Application number
MX9704640A
Other languages
English (en)
Inventor
Todd K Jones
Mark E Goldman
Pooley L F Charlotte
David T Winn
James E Edwards
Sarah J West
Christopher M Tegley
Lin Zhi
Lawrence G Hamann
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Priority claimed from PCT/US1995/016096 external-priority patent/WO1996019458A2/en
Publication of MX9704640A publication Critical patent/MX9704640A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen compuestos no esteroides que son moduladores de alta selectividad, alta afinidad para los receptores de esteroides. También se describen composiciones farmacéuticas que incorporan tales compuestos, métodos para emplear los compuestos y composiciones descritos para tratar pacientes que requieren terapia de agonista o antagonista del receptor de esteroides, intermediarios utiles en la preparacion de los compuestos y procesos para la preparacion de los compuestos moduladores de los receptores de esteroides.
MX9704640A 1994-12-22 1995-12-13 Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. MX9704640A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36352994A 1994-12-22 1994-12-22
PCT/US1995/016096 WO1996019458A2 (en) 1994-12-22 1995-12-13 Steroid receptor modulator compounds and methods

Publications (1)

Publication Number Publication Date
MX9704640A true MX9704640A (es) 1997-10-31

Family

ID=23430606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704640A MX9704640A (es) 1994-12-22 1995-12-13 Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.

Country Status (3)

Country Link
US (11) US5693646A (es)
KR (1) KR100546740B1 (es)
MX (1) MX9704640A (es)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
HRP960352A2 (en) * 1996-07-26 1998-08-31 Pliva Pharm & Chem Works Novel coumarin quinoline carboxylic acids
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6093825A (en) * 1998-05-27 2000-07-25 American Home Products Methods for preparation of 1,2-dihydroquinolines
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6083956A (en) * 1998-11-20 2000-07-04 Pfizer Inc. Optically pure androgen mediator
EE05584B1 (et) 1999-04-30 2012-10-15 Pfizer Products Inc. Glkokortikoidretseptori modulaatorid
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
EP1173213A1 (en) * 1999-05-04 2002-01-23 American Home Products Corporation Compositions containing benzimidazolones and progestogens
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
CN1353717A (zh) * 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法
CZ20013952A3 (cs) * 1999-05-04 2002-05-15 American Home Products Corporation Deriváty cyklothiokarbamátu jako modulátory receptoru pro progesteron
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
WO2000066592A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6380178B1 (en) * 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US20060115826A1 (en) * 1999-06-28 2006-06-01 Michael Bevilacqua Gene expression profiling for identification monitoring and treatment of multiple sclerosis
US20050060101A1 (en) * 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20040225449A1 (en) * 1999-06-28 2004-11-11 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using selected gene expression profiles
CN1391576A (zh) 1999-08-27 2003-01-15 利甘德药品公司 雄激素受体调节剂化合物及方法
CA2378298A1 (en) 1999-08-27 2001-03-08 Lawrence G. Hamann 8-substituted-6-trifluoromethyl-9-pyrido¬3,2-g|quinoline compounds as androgen receptor modulators
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
ATE375160T1 (de) * 1999-08-31 2007-10-15 Bayer Schering Pharma Ag Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
CN1082556C (zh) * 1999-08-31 2002-04-10 蒲忠杰 一种用于营养型洁净饮用水的合金材料
WO2001019770A2 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
EP1955700B9 (en) 1999-09-30 2011-09-07 Harbor BioSciences, Inc. Therapeutic treatment of androgen receptor driven conditions
AU1330901A (en) * 1999-10-06 2001-05-10 Brigham And Women's Hospital Compounds and methods for modulating non-transcriptional effects of steroid hormones
WO2001027622A1 (en) * 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US6172241B1 (en) * 1999-10-15 2001-01-09 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
DE60130748T2 (de) 2000-03-27 2008-07-17 N.V. Organon Nicht-steroidale tetracyclische verbindungen für östrogen-verwandte behandlungen
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7713989B2 (en) * 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
EP1325914A4 (en) * 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
ES2246292T3 (es) * 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6599921B2 (en) * 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
FR2825268B1 (fr) * 2001-05-31 2004-09-17 Oreal Composition cosmetique comprenant des particules de carbonate de calcium et des agents de conditionnement
US6852876B1 (en) 2001-06-08 2005-02-08 University Of Central Florida Treatment of colon cancer
US6686496B1 (en) 2001-06-08 2004-02-03 University Of Central Florida Treatment of myeloma
US6602907B1 (en) 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
KR100647161B1 (ko) 2001-08-24 2006-11-23 인텔 코오퍼레이션 레거시 인터럽트를 지원하는 범용 입/출력 아키텍쳐프로토콜 및 관련 방법
US9836424B2 (en) 2001-08-24 2017-12-05 Intel Corporation General input/output architecture, protocol and related methods to implement flow control
US7177971B2 (en) * 2001-08-24 2007-02-13 Intel Corporation General input/output architecture, protocol and related methods to provide isochronous channels
US7027092B2 (en) * 2001-09-17 2006-04-11 Hewlett-Packard Development Company, L.P. Image capture and storage device
ES2291507T3 (es) * 2001-10-19 2008-03-01 MERCK & CO., INC. Moduladores de receptor de androgenos y procedimientos de uso de los mismos.
WO2003040404A1 (en) * 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
TW200304371A (en) * 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
AU2003230581A1 (en) * 2002-03-15 2003-09-29 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DE60318188T2 (de) * 2002-03-26 2008-12-11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
TWI297685B (en) * 2002-04-04 2008-06-11 Organon Nv Non-steroidal progesterone receptor modulators
CA2484340C (en) * 2002-04-26 2011-05-03 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR20050057086A (ko) 2002-08-28 2005-06-16 홀리스-에덴 파마슈티칼즈, 인코포레이티드 치료적 처치 방법
EP1539141B1 (en) * 2002-08-29 2010-07-14 Boehringer Ingelheim Pharmaceuticals Inc. 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
GB0222516D0 (en) * 2002-09-27 2002-11-06 Karobio Ab Novel compounds
MXPA05003721A (es) * 2002-10-11 2005-06-17 Ligand Pharm Inc Derivados de 5-cicloalquenilo-5h-cromeno[3,4-f]quinolina como compuestos moduladores, selectivos de receptores de progesterona.
DE20301728U1 (de) * 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1558618A1 (en) * 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
US8012603B2 (en) 2002-10-30 2011-09-06 Sumitomo Chemical Company, Limited Polymer compound and polymer light-emitting device using the same
WO2004045518A2 (en) * 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
AU2004266160A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
CA2545020A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
WO2005051293A2 (en) 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) * 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7553967B2 (en) * 2004-03-12 2009-06-30 Wyeth 1,2-Dihydroquinoline derivatives and method for using the same to treat HIV infections
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
TW200531977A (en) * 2004-03-25 2005-10-01 Akzo Nobel Nv Progesterone receptor modulators
KR20070056060A (ko) * 2004-07-14 2007-05-31 리간드 파마슈티칼스 인코포레이티드 세포내 수용체 조절화합물 및 방법
ATE514700T1 (de) 2004-09-20 2011-07-15 Janssen Pharmaceutica Nv Neues tetrazyklisches heteroatom mit als sexualsteroidhormon-rezeptormodulatoren geeigneten derivaten
US7759498B2 (en) * 2004-09-20 2010-07-20 Janssen Pharmaceutica N.V Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
ES2341268T3 (es) * 2004-10-27 2010-06-17 Janssen Pharmaceutica Nv Tiofenos trisubstituidos utilizados como antagonistas del receptor de la progesterona.
MX2007007103A (es) * 2004-12-13 2008-03-10 Lilly Co Eli Derivados espiro como inhibidores de lipoxigenasa.
JP2008525525A (ja) * 2004-12-27 2008-07-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物及び使用
CN101137655A (zh) * 2005-06-17 2008-03-05 配体药物公司 雄激素受体调节剂化合物和方法
CA2620275A1 (en) * 2005-08-26 2007-03-01 Thomas S. Scanlan Non-steroidal antiandrogens
EP1944290B1 (en) 2005-09-14 2013-12-04 Santen Pharmaceutical Co., Ltd. Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
KR100878443B1 (ko) * 2006-04-06 2009-01-13 주식회사 오스코텍 Ｏｐｇ 분비를 촉진하는 대사성 골 질환의 예방 및 치료제
US7989442B2 (en) * 2006-09-27 2011-08-02 N.V. Organon Progesterone receptor modulators
LT2078032T (lt) 2006-10-24 2017-11-10 Repros Therapeutics Inc. Kompozicijos ir būdai, skirti gimdos gleivinės proliferacijos slopinimui
PL2085388T3 (pl) 2006-11-14 2013-01-31 Santen Pharmaceutical Co Ltd Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
CA2671990A1 (en) * 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
US8063037B2 (en) * 2007-05-07 2011-11-22 N. V. Organon Progesterone receptor modulators
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
KR20110010634A (ko) * 2008-05-12 2011-02-01 산텐 세이야꾸 가부시키가이샤 치환 옥시기를 가지는 2,2,4-트리메틸-6-페닐-1,2-디하이드로퀴놀린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
AU2009256289A1 (en) * 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009152210A2 (en) * 2008-06-12 2009-12-17 National Health Research Institutes Coumarin compounds and their use for treating cancer
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
AU2010280323A1 (en) 2009-07-31 2012-03-08 Cadila Healthcare Limited Novel compounds as modulators of glucocorticoid receptors
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN102906103A (zh) 2010-03-22 2013-01-30 利普生物药剂公司 用于抗孕酮的非毒性递送的组合物和方法
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
JP5747391B2 (ja) 2010-03-26 2015-07-15 ガルデルマ・リサーチ・アンド・デヴェロップメント 紅斑の安全かつ有効な治療のための改善された方法および組成物
US11103514B2 (en) 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
RS53531B1 (en) 2010-10-21 2015-02-27 Galderma S.A. Brimonidine gel composition
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2014348191B2 (en) 2013-11-18 2019-03-28 Forma Therapeutics Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
CA2977591A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
JP6768789B2 (ja) 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
ES2861524T3 (es) 2016-01-19 2021-10-06 Corcept Therapeutics Inc Diagnóstico diferencial del Síndrome de Cushing Ectópico
JP7563882B2 (ja) 2017-03-31 2024-10-08 コーセプト セラピューティクス， インコーポレイテッド 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター
JP2020524152A (ja) 2017-06-20 2020-08-13 コーセプト セラピューティクス， インコーポレイテッド 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
FR3072286B1 (fr) * 2017-10-13 2022-08-12 Oreal 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
MX2021007322A (es) 2018-12-19 2021-07-07 Corcept Therapeutics Inc Formulaciones farmaceuticas que contienen relacorilant, un compuesto de azadecalina fusionado con heteroaril-cetona.
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11058670B2 (en) 2019-02-22 2021-07-13 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
JP7629913B2 (ja) 2019-10-16 2025-02-14 コーセプト セラピューティクス， インコーポレイテッド 選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球／リンパ球比を正常化する方法
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN115160310B (zh) * 2022-05-10 2023-06-23 中国人民解放军北部战区总医院 作为CDK2/Topo I抑制剂的白叶藤碱衍生物及其制备方法和抗肿瘤的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2562970A (en) * 1950-04-14 1951-08-07 Thompson Chester Ray Preservation of forage crops
US2661277A (en) * 1952-09-12 1953-12-01 Monsanto Chemicals Herbicides
US3095353A (en) * 1960-03-30 1963-06-25 Monsanto Chemicals Aqueous mixture of surface active agents
US2989963A (en) * 1960-04-27 1961-06-27 Monsanto Chemicals Agricultural process
NL126509C (es) * 1961-10-30
JPS492127B1 (es) * 1970-11-13 1974-01-18
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3979394A (en) * 1970-12-11 1976-09-07 Agfa-Gevaert N.V. Duplo quinoline compounds
GB1400993A (en) * 1971-11-10 1975-07-16 Agfa Gevaert Electrophotographic material
BE795696A (nl) * 1972-02-28 1973-08-21 Agfa Gevaert Nv Voor warmte gevoelige materialen
SU555119A1 (ru) * 1975-05-19 1977-04-25 Предприятие П/Я Г-4913 Вулканизуема резинова смесь на основе полиизопренового каучука
US4380634A (en) * 1978-10-16 1983-04-19 The United States Of America As Represented By The Secretary Of The Navy Method of preparing 2-keto-4,6,8,8-tetramethyl-8,9-dihydro-2H-pyrano-(3,2-g) quinoline, a blue-green laser dye
EP0072349B1 (de) * 1981-08-10 1987-05-13 Ciba-Geigy Ag Tetrahydrochinoline als Antioxidantien für Schmiermittel
US4479223A (en) * 1982-08-02 1984-10-23 The United States Of America As Represented By The Secretary Of The Navy Adaptation for improving lifetime of dye laser using coumarin dyes
LU84492A1 (de) * 1982-11-29 1984-06-13 F C De Schryver Cumarin-derivate,verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische praeparate
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US4956372A (en) * 1987-10-02 1990-09-11 Kyorin Pharmaceutical Co., Ltd. Cyclic anthranilic acid derivatives and process for their preparation
DE68916592T2 (de) * 1988-06-23 1994-12-01 Agfa Gevaert Nv Für elektrophotographische Zwecke geeignetes photoempfindliches Aufzeichnungsmaterial.
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5208263A (en) 1988-09-30 1993-05-04 Arch Development Corporation Anti-androgen compounds
ES2245660T3 (es) 1990-11-30 2006-01-16 Otsuka Pharmaceutical Co., Ltd. Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.
JPH04316557A (ja) * 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
US5147844A (en) * 1991-06-14 1992-09-15 Eastman Kodak Company Mixture on cyan and yellow dyes to form a green hue for color filter array element
TW234124B (es) * 1992-07-15 1994-11-11 Sumitomo Chemical Co
US5283336A (en) * 1992-09-08 1994-02-01 The United States Of America As Represented By The United States Department Of Energy Method for preparation of 7-hydroxy-1,2,3,4-tetrahydroquinoline from 1,2,3,4-tetrahydroquinoline
US5272146A (en) * 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods

Also Published As

Publication number Publication date
US5696130A (en) 1997-12-09
US5688808A (en) 1997-11-18
US6448405B1 (en) 2002-09-10
US5693647A (en) 1997-12-02
US5696133A (en) 1997-12-09
US5994544A (en) 1999-11-30
US5688810A (en) 1997-11-18
KR100546740B1 (ko) 2006-01-26
US5693646A (en) 1997-12-02
US6093821A (en) 2000-07-25
US5696127A (en) 1997-12-09
US6121450A (en) 2000-09-19
KR20040044543A (ko) 2004-05-28

Similar Documents

Publication Publication Date Title
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
AU4597796A (en) Steroid receptor modulator compounds and methods
AU3508497A (en) Androgen receptor modulator compounds and methods
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU7362496A (en) Dimer-selective rxr modulators and methods for their use
BG106142A (en) Glucocorticoid receptor modulators
EP0911321A3 (en) Compounds for the treatment of osteoporosis
EP0785793A4 (en) ALLOSTERIC MODULATORS OF THE NMDA RECEPTOR
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
BG102726A (en) Combined therapy for osteoporosis
AP9801269A0 (en) Prostaglandin agonists.
ATE205480T1 (de) 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
CA2259031A1 (en) Androgen receptor modulator compounds and methods
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.
MX9706967A (es) Indazolcarboxamidas.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees